DANISH-Studie – ICD bei Patienten mit nicht ischämischer Kardiomyopathie?

Daniel Matthias Burgard; Wolfgang Schöls

doi:10.1055/a-0674-6684

Kardiologie up2date, Table of Contents

Kardiologie up2date 2019; 15(04): 303-314
DOI: 10.1055/a-0674-6684

Herzrhythmusstörungen

Georg Thieme Verlag KG Stuttgart · New York

DANISH-Studie – ICD bei Patienten mit nicht ischämischer Kardiomyopathie?

Daniel Matthias Burgard

,

Wolfgang Schöls

Abstract

All articles of this category

Die DANISH-Studie ist die neueste Publikation, die sich mit der primären Prävention des plötzlichen Herztods bei nicht ischämischer Kardiomyopathie auseinandersetzt. Auf den ersten Blick hat die ICD-Implantation dabei keinen statistisch relevanten Effekt auf die Gesamtsterblichkeit. Im Folgenden sollen Therapie und prophylaktische Möglichkeiten bei der NICMP dargestellt und dieser erste Eindruck dabei relativiert werden.

Schlüsselwörter

DANISH - implantierbarer Kardioverter-Defibrillator (ICD) - nicht ischämische Kardiomyopathie (NICM)

Full Text

References

Literatur
1 Pinto YM, Elliott PM, Arbustini E. et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 2016; 37: 1850-1858 doi:10.1093/eurheartj/ehv727
2 Mestroni L, Maisch B, McKenna WJ. et al. Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J 1999; 20: 93-102
3 Richard P, Villard E, Charron P. et al. The Genetic Bases of Cardiomyopathies. J Am Coll Cardiol 2006; 48 (9, Suppl.): A79-A89 doi:10.1016/j.jacc.2006.09.014
4 Caforio ALP, Pankuweit S, Arbustini E. et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34: 2636-2648 2648a–2648d doi:10.1093/eurheartj/eht210
5 Felker GM, Thompson RE, Hare JM. et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342: 1077-1084 doi:10.1056/NEJM200004133421502
6 Teeter WA, Thibodeau JT, Rao K. et al. The natural history of new-onset heart failure with a severely depressed left ventricular ejection fraction: implications for timing of implantable cardioverter-defibrillator implantation. Am Heart J 2012; 164: 358-364 doi:10.1016/j.ahj.2012.06.009
7 Levy D, Kenchaiah S, Larson MG. et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397-1402 doi:10.1056/NEJMoa020265
8 Narang R, Cleland JG, Erhardt L. et al. Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J 1996; 17: 1390-1403
9 Teerlink JR, Jalaluddin M, Anderson S. et al. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. Circulation 2000; 101: 40-46
10 Koilpillai C, Quinones MA, Greenberg B. et al. Relation of ventricular size and function to heart failure status and ventricular dysrhythmia in patients with severe left ventricular dysfunction. Am J Cardiol 1996; 77: 606-611
11 Ponikowski P, Voors AA, Anker SD. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureThe Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-2200 doi:10.1093/eurheartj/ehw128
12 Swedberg K, Komajda M, Bohm M. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-885 doi:10.1016/S0140-6736(10)61198-1
13 McMurray V JJ, Packer M, Desai AS. et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2013; 15: 1062-1073 doi:10.1093/eurjhf/hft052
14 Cleland JG, Daubert JC, Erdmann E. et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-1549 doi:10.1056/NEJMoa050496
15 Ypenburg C, van Bommel RJ, Borleffs CJW. et al. Long-term prognosis after cardiac resynchronization therapy is related to the extent of left ventricular reverse remodeling at midterm follow-up. J Am Coll Cardiol 2009; 53: 483-490 doi:10.1016/j.jacc.2008.10.032
16 Mullens W, Bartunek J, Tang WHW. et al. Early and late effects of cardiac resynchronization therapy on force-frequency relation and contractility regulating gene expression in heart failure patients. Heart Rhythm 2008; 5: 52-59 doi:10.1016/j.hrthm.2007.09.009
17 McAlister FA, Ezekowitz J, Hooton N. et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA 2007; 297: 2502-2514 doi:10.1001/jama.297.22.2502
18 Biton Y, Kutyifa V, Cygankiewicz I. et al. Relation of QRS Duration to Clinical Benefit of Cardiac Resynchronization Therapy in Mild Heart Failure Patients Without Left Bundle Branch Block: The Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy Substudy. Circ Heart Fail 2016; 9: e002667 doi:10.1161/CIRCHEARTFAILURE.115.002667
19 Peterson PN, Greiner MA, Qualls LG. et al. QRS duration, bundle-branch block morphology, and outcomes among older patients with heart failure receiving cardiac resynchronization therapy. JAMA 2013; 310: 617-626 doi:10.1001/jama.2013.8641
20 Curtis AB, Worley SJ, Adamson PB. et al. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med 2013; 368: 1585-1593 doi:10.1056/NEJMoa1210356
21 Bristow MR, Saxon LA, Boehmer J. et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-2150 doi:10.1056/NEJMoa032423
22 Lam SKH, Owen A. Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials. BMJ 2007; 335: 925 doi:10.1136/bmj.39343.511389.BE
23 Camm AJ, Pratt CM, Schwartz PJ. et al. Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation 2004; 109: 990-996 doi:10.1161/01.CIR.0000117090.01718.2A
24 Singer I, Al-Khalidi H, Niazi I. et al. Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. J Am Coll Cardiol 2004; 43: 39-43
25 Hallstrom A, Pratt CM, Greene HL. et al. Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac Arrhythmia Suppression Trial. J Am Coll Cardiol 1995; 25: 1250-1257
26 Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576-1583 doi:10.1056/NEJM199711273372202
27 Kuck KH, Cappato R, Siebels J. et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102: 748-754
28 Connolly SJ, Gent M, Roberts RS. et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101: 1297-1302
29 Lee DS, Green LD, Liu PP. et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. J Am Coll Cardiol 2003; 41: 1573-1582
30 Desai AS, Fang JC, Maisel WH. et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA 2004; 292: 2874-2879 doi:10.1001/jama.292.23.2874
31 Kadish A, Dyer A, Daubert JP. et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350: 2151-2158 doi:10.1056/NEJMoa033088
32 Bansch D, Antz M, Boczor S. et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 2002; 105: 1453-1458
33 Bardy GH, Lee KL, Mark DB. et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237 doi:10.1056/NEJMoa043399
34 Saxon LA, Bristow MR, Boehmer J. et al. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circulation 2006; 114: 2766-2772 doi:10.1161/CIRCULATIONAHA.106.642892
35 Woods B, Hawkins N, Mealing S. et al. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. Heart 2015; 101: 1800-1806 doi:10.1136/heartjnl-2015-307634
36 Kober L, Thune JJ, Nielsen JC. et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med 2016; 375: 1221-1230 doi:10.1056/NEJMoa1608029
37 Al-Khatib SM, Hellkamp AS, Fonarow GC. et al. Association between prophylactic implantable cardioverter-defibrillators and survival in patients with left ventricular ejection fraction between 30% and 35%. JAMA 2014; 311: 2209-2215 doi:10.1001/jama.2014.5310
38 Gimbel JR, Mackall J. Does Anyone Really Believe the Results of the DANISH Trial? Implanting an ICD in Nonischemic Cardiomyopathy Patients. Pacing Clin Electrophysiol 2017; 40: 459-462 doi:10.1111/pace.13054
39 Elming MB, Nielsen JC, Haarbo J. et al. Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure. Circulation 2017; 136: 1772-1780 doi:10.1161/CIRCULATIONAHA.117.028829
40 Ponikowski P, Voors AA, Anker SD. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-2200 doi:10.1093/eurheartj/ehw128
41 Priori SG, Blomström-Lundqvist C, Mazzanti A. et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015; 36: 2793-2867 doi:10.1093/eurheartj/ehv316
42 McAlister FA, Ezekowitz J, Hooton N. et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA 2007; 297: 2502-2514 doi:10.1001/jama.297.22.2502
43 Brignole M, Moya A, de Lange FJ. et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J 2018; 39: 1883-1948 doi:10.1093/eurheartj/ehy037
44 Siscovik DS. Challenges in cardiac arrest research: data collection to assess outcomes. Ann Emerg Med 1993; 22: 92